Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of HP184 in chronic spinal cord injury
2004-000763-98Phase 2Completed
- Sponsor
- Sanofi
- Start
- Jul 2005
- Modality
- Classical Binding Small Molecules → Small Molecules, Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of nerispirdine in spinal cord injury (SCI) (4 arms), sponsored by Sanofi. Primary endpoint: Responder rate in ASIA total motor score at Week 24. Started Jul 2005; status: completed.
02
Drugs
nerispirdine
03
Conditions
spinal cord injury (SCI)
Beyond the preview
Go deeper on 2004-000763-98.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000763-98.